Syndax Q3 Revenue Reaches $83.298 Million
Syndax Pharmaceuticals reported Q3 revenue of USD 83.298 million versus the IBES estimate of USD 81.8 million.
Related stories
Black Stone Minerals reports third-quarter earnings
Black Stone Minerals LP reported third-quarter earnings, according to the headline and available body text.
M impact | EQUITY | Nov 02, 2026, 11:07 PM UTC
Stock exchange approves NICE listing withdrawal effective Nov. 6, 2026
The stock exchange approved the withdrawal of NICE’s listing, effective November 6, 2026.
M impact | EQUITY | Nov 02, 2026, 11:05 PM UTC
I-80 Gold Posts Q3 Adjusted Loss of $0.06 Per Share
M impact | EQUITY | Nov 02, 2026, 11:04 PM UTC
I-80 Gold reports Q3 production of 11,685 ounces
M impact | EQUITY | Nov 02, 2026, 11:04 PM UTC
Backblaze Raises Full-Year Revenue Outlook; Shares Surge 33% After Hours
Backblaze raised its full-year revenue outlook. Shares rose 33% to $9.84 in after-hours trading Monday, after closing down 2.5% at $7.40; the stock is up 59% year to date.
M impact | EQUITY | Nov 02, 2026, 11:04 PM UTC
AH Realty Trust Q3 Earnings Snapshot
AH Realty Trust reported on Monday; the available text provides no earnings figures.
M impact | EQUITY | Nov 02, 2026, 11:03 PM UTC